Trial Profile
OPEN-LABEL, 2-DOSE LEVEL TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ESLICARBAZEPINE ACETATE (ESL) AS ADJUNCTIVE THERAPY IN INFANTS WITH REFRACTORY EPILEPSY WITH PARTIAL-ONSET SEIZURES AGED FROM 1 MONTH TO <2 YEARS
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jul 2022
Price :
$35
*
At a glance
- Drugs Eslicarbazepine acetate (Primary)
- Indications Partial epilepsies
- Focus Pharmacokinetics
- Sponsors Bial
- 05 Jul 2020 Status changed from recruiting to completed.
- 04 Sep 2017 New trial record